Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies - Yang, Yaru; Qiu, Hongyan; Fan, Yuru; Zhang, Qin; Qin, Huiling; Wu, Juan; Zhang, Xuan; Liu, Yueyue; Zhou, Renpeng; Zhang, Qian; Ye, Zi; Ma, Jingyue; et al. (Alzheimer's research & therapy, 2024)
Keywords: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Alzheimer's disease; Amyloid beta-Peptides; anti-Aβ monoclonal antibody; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - pharmacokinetics; Antibodies, Monoclonal, Humanized - pharmacology; Brain research; Care and treatment; Clinical trial; Clinical trials; Dose-Response Relationship, Drug; Double-Blind Method; Drug discovery; Female; Genetic engineering; Healthy Volunteers; Humans; Immunoglobulin G; Male; Methods; Middle Aged; Monoclonal antibodies; Pharmacodynamics; Pharmacokinetics; Safety and security measures; Testing; Young Adult; China; Australia; Clinical trial; anti-Aβ monoclonal antibody; Pharmacodynamics; Alzheimer’s disease; Pharmacokinetics